plenvu - proszek do sporządzania roztworu doustnego
norgine b.v. - makrogol 3350 + sodu siarczan bezwodny + sodu chlorek + potasu chlorek + sodu askorbinian + kwas askorbowy - proszek do sporządzania roztworu doustnego - -
menopur 150 iu fsh + 150 iu lh proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań
ferring gmbh - menotropinum (fsh i lh) - proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań - 150 iu fsh + 150 iu lh
xeljanz
pfizer europe ma eeig - Тофацитиниб - zapalenie stawów, reumatoidalne - leki immunosupresyjne - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 i 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
alortia 50 mg + 5 mg tabletki powlekane
krka, d.d., novo mesto - losartanum kalicum + amlodipinum - tabletki powlekane - 50 mg + 5 mg
alortia 50 mg + 10 mg tabletki powlekane
krka, d.d., novo mesto - losartanum kalicum + amlodipinum - tabletki powlekane - 50 mg + 10 mg
alortia 100 mg + 10 mg tabletki powlekane
krka, d.d., novo mesto - losartanum kalicum + amlodipinum - tabletki powlekane - 100 mg + 10 mg
alortia 100 mg + 5 mg tabletki powlekane
krka, d.d., novo mesto - losartanum kalicum + amlodipinum - tabletki powlekane - 100 mg + 5 mg
hydroxychloroquine adamed 200 mg tabletki powlekane
adamed pharma s.a. - hydroksychlorochina - tabletki powlekane - 200 mg
gripex hot intense 1000 mg + 50 mg + 12,2 mg proszek do sporządzania roztworu doustnego w saszetce
us pharmacia sp. z o.o. - paracetamolum + coffeinum + phenylephrini hydrochloridum - proszek do sporządzania roztworu doustnego w saszetce - 1000 mg + 50 mg + 12,2 mg
oftahist 1 mg/ml krople do oczu, roztwór
adamed pharma s.a. - olopatadinum - krople do oczu, roztwór - 1 mg/ml